Donald L Lappe
Overview
Explore the profile of Donald L Lappe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Horne B, Roberts C, Rasmusson K, Buckway J, Alharethi R, Cruz J, et al.
Am Heart J
. 2019 Nov;
219:78-88.
PMID: 31739181
Objective: Using augmented intelligence clinical decision tools and a risk score-guided multidisciplinary team-based care process (MTCP), this study evaluated the MTCP for heart failure (HF) patients' 30-day readmission and 30-day...
12.
Anderson J, Jacobs V, May H, Bair T, Benowitz B, Lappe D, et al.
J Cardiovasc Electrophysiol
. 2019 Sep;
31(1):18-29.
PMID: 31515856
Introduction: Hyperthyroidism is a known precipitating factor for atrial fibrillation (AF). However, recent reports have suggested an increased risk of AF with free thyroxine (fT4) levels even within the upper...
13.
Muhlestein J, Hackett I, May H, Bair T, Le V, Anderson J, et al.
Am J Cardiol
. 2019 Apr;
123(12):1927-1934.
PMID: 30981419
Glycoprotein IIb/IIIa inhibitors, used as a standard intravenous bolus followed by a prolonged infusion for 12 to 18 hours, reduces ischemic complications during percutaneous coronary interventions (PCI) but often at...
14.
Graves K, May H, Jacobs V, Knowlton K, Muhlestein J, Lappe D, et al.
Heart Rhythm
. 2019 Jan;
16(1):3-9.
PMID: 30611392
Background: High CHADS-VASc scores in atrial fibrillation (AF) patients are generally associated with increased risks of stroke and dementia. At lower CHADS-VASc scores, there remains an unquantifiable cranial injury risk,...
15.
May H, Lappe D, Knowlton K, Muhlestein J, Anderson J, Horne B
Mayo Clin Proc
. 2018 Dec;
94(7):1221-1230.
PMID: 30577973
Objective: To apply the practical parsimonious modeling method of the Intermountain Mortality Risk Score in a primary care environment to predict chronic disease (ChrD) onset. Patients And Methods: Primary care...
16.
Graves K, May H, Knowlton K, Muhlestein J, Jacobs V, Lappe D, et al.
Open Heart
. 2018 Dec;
5(2):e000907.
PMID: 30564375
Background: Oral anticoagulation (OAC) therapy guidelines recommend using CHADS-VASc to determine OAC need in atrial fibrillation (AF). A usable tool, CHADS-VASc is challenged by its predictive ability. Applying components of...
17.
Horne B, Muhlestein J, Bennett S, Muhlestein J, Jensen K, Marshall D, et al.
JCI Insight
. 2018 Jul;
3(14).
PMID: 30046011
Background: The red cell distribution width (RDW) is associated with health outcomes. Whether non-RDW risk information is contained in RBC sizes is unknown. This study evaluated the association of the...
18.
Muhlestein J, May H, Galenko O, Knowlton K, Otvos J, Connelly M, et al.
Am Heart J
. 2018 May;
202:27-32.
PMID: 29803983
Background: GlycA is an inflammatory marker that is raised in patients with cardiometabolic diseases and associated with cardiovascular (CV) events. We sought to determine if GlycA adds independent value to...
19.
Knight S, Min D, Le V, Meredith K, Dhar R, Biswas S, et al.
JCI Insight
. 2018 May;
3(9).
PMID: 29720565
Background: Cardiac positron emission testing (PET) is more accurate than single photon emission computed tomography (SPECT) at identifying coronary artery disease (CAD); however, the 2 modalities have not been thoroughly...
20.
Anderson J, Knowlton K, May H, Bair T, Armstrong S, Lappe D, et al.
J Clin Lipidol
. 2018 Apr;
12(4):1008-1018.e1.
PMID: 29703626
Background: Statins are indicated for secondary atherosclerotic cardiovascular disease (ASCVD) prevention; however, multiple surveys have found treatment gaps in clinical application. Objective: To determine trends over 15 years in the...